Theralase Q1 FY26 net loss narrows 29.9% to C$1.03 million; revenue rises 45% to C$132,634

20+ Year Trsy Bond Ishares

20+ Year Trsy Bond Ishares

TLT

0.00
  • Theralase reported Q1 revenue rose 45% to CAD 132,634.
  • Gross margin widened to 49% from 15% a year earlier, with cost of sales at CAD 68,250.
  • Net loss narrowed 29.89% to CAD 1.03 million, including CAD 172,118 in non-cash expenses.
  • R&D expense fell 36% to CAD 564,724 as Study II patient enrollment and treatment costs declined toward completion.
  • Study II interim data showed a 65.2% complete response rate (58/89); Theralase targets an NDA filing in 3Q2026, with decisions expected in 1H2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Theralase Technologies Inc. published the original content used to generate this news brief on May 29, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.